Diabetes Clinical Trials Show Critical Gaps in Physical Examination Documentation and Standardization

What Do Diabetes Trials Reveal About Physical Examinations?

A comprehensive analysis of phase 3 and 4 diabetes clinical trials reveals that physical examinations (PEs) are ubiquitous yet poorly documented components in research protocols. This systematic review of 211 type 2 diabetes mellitus (T2DM) trial protocols found that while 90% included at least one PE, there was striking inconsistency in how these examinations were described and conducted. The findings raise important questions about standardization practices in clinical trials and whether physical examinations are being included more from convention than necessity. The research team from the Trials@Home consortium analyzed protocols extracted from ClinicalTrials.gov, assessing the frequency, timing, purpose, elements, and conduct of physical examinations in late-phase diabetes drug trials. Their results highlight significant gaps in protocol documentation that may impact trial quality, consistency, and the potential for decentralized approaches to clinical research. In an era where patient-centric trial designs are increasingly prioritized, understanding the role and requirements of physical examinations becomes particularly relevant for determining which trial activities truly require in-person visits.

The study identified 241 distinct physical examinations across the analyzed protocols, categorizing them as "general PE" (in protocols with only one type of PE) or as "complete" and "brief" PEs (in protocols with multiple PE types). The timing of physical examinations was well-documented, with 88% scheduled during screening visits, 83% at final visits, and 64% at interim visits during the trial. However, critical information was frequently missing: only 67% explicitly stated the purpose of the PE, 60% described what elements should be examined, and a mere 8% provided details on how the examination should be conducted. When purposes were documented, the most common were detecting adverse events (40%), identifying trial endpoints (33%), and assessing eligibility (21%). Interestingly, protocols with multiple types of PEs provided more comprehensive documentation than those with a single type, suggesting more deliberate consideration of the examination's role. Among the bodily systems assessed, the cardiovascular system was most frequently documented (95% of PEs that specified elements), followed by the respiratory system (90%) and digestive system (74%). Vital signs and anthropometric measurements were specifically included as part of the PE in only about one-quarter of all examinations, though these measurements might have been mentioned elsewhere in protocols. Perhaps most concerning was that three-quarters of PEs did not specify who should conduct the examination, and almost all (99%) were scheduled to take place during study visits at the site or research center, with only one documented to be conducted remotely.

How Do Inconsistent Examinations Affect Trial Outcomes?

The findings point to several important implications for clinical trial design and conduct. First, the lack of standardized documentation raises concerns about inter-observer variation and data quality, particularly in multi-site international trials where differences in training and practice may exist. Without clear guidance, investigators may perform examinations with varying degrees of thoroughness, potentially affecting eligibility determinations and safety assessments. Second, the absence of explicitly stated purposes for many PEs raises questions about whether these examinations are included out of necessity or merely from convention. In an environment where data minimization principles (such as those in the General Data Protection Regulation) emphasize collecting only necessary data and where reducing participant burden is increasingly prioritized, the automatic inclusion of PEs deserves reconsideration. The authors suggest that being explicit about the purpose of PE would allow for more rational decisions about its scope and necessity in each trial. This becomes particularly relevant as the field moves toward decentralized clinical trial approaches, where traditional site visits may be reduced or eliminated. The researchers note that while physical examinations may serve important purposes beyond their clinical objectives—such as building rapport between participants and trial personnel—these benefits should be weighed against the burdens they impose and potential alternatives for achieving the same ends.

The study has several strengths, including its large sample size and rigorous assessment methodology with double assessment of complex protocols, but also limitations. The analysis focused exclusively on T2DM trials with protocols available in ClinicalTrials.gov, potentially limiting generalizability to other therapeutic areas where physical examinations might play different roles. For instance, in dermatology trials, where physical findings may constitute primary endpoints, PEs might be described with greater detail. Additionally, the findings may not extend to early-phase trials, where safety profiles are less established and more comprehensive monitoring might be warranted. Despite these limitations, the study offers valuable insights into current practices and highlights opportunities for improvement. The authors recommend that trial protocols explicitly state the purpose of any included PE, determine its appropriate scope based on that purpose, and provide detailed documentation to ensure standardization. They also suggest exploring alternative approaches, such as telemedicine solutions for remote examinations or leveraging existing electronic medical record data, particularly for late-phase trials where safety profiles are better understood. Could more explicit documentation of physical examination requirements lead to higher quality and more consistent trial data? How might the field balance the need for standardization with the goal of reducing participant burden in clinical trials?

What Does the Protocol Data Tell Us About Study Rigor?

The researchers extracted data from 211 clinical trial protocols of phase 3 and 4 drug interventional trials with T2DM, after excluding 16 protocols that did not meet inclusion criteria. The majority of these trials (96%) had multiple arms, with a median duration of 781 days and a median of 324 participants planned to be randomized per trial. Participants' trial duration averaged 229 days, reflecting the substantial time commitment required for these studies. Nearly half the trials (49%) were conducted across multiple countries, with a median of 41 sites per protocol, highlighting the international and multi-center nature of late-phase diabetes research.

The study's methodological approach was rigorous, with five researchers collecting data using a study-specific assessment form that was tested and refined through iterative sessions. Twenty pilot protocols were initially assessed to ensure consistency among researchers, and all data were entered into an electronic data form using Castor. Protocols deemed difficult to assess were flagged for double assessment, which occurred for 18 protocols, with discrepancies resolved through team discussion until consensus was reached. This careful approach to data collection strengthens the reliability of the findings.

In examining the elements of physical examinations, the researchers found that when PE elements were specified (in 60% of PEs), they were most commonly described at the bodily system level (79%), followed by the general system level (60%). Complete PEs were more likely to include "other specified examinations" (65%) compared to brief PEs (41%) and general PEs (14%). When examining specific bodily systems, the cardiovascular system was most frequently documented (95%), followed closely by the respiratory system (90%). The musculoskeletal system was mentioned in 36% of PEs that specified elements, while the urinary system (2%) and reproductive system (3%) were rarely documented. These findings reflect the emphasis on cardiovascular assessment in diabetes trials, consistent with the disease's known complications.

Do Current Guidelines Adequately Shape Trial Practices?

The American Diabetes Association (ADA) recommends that height, weight, BMI, blood pressure, skin examination, and visual inspection of the foot should be assessed at each follow-up visit in clinical practice. While the cardiovascular system (likely including blood pressure) was frequently documented in trial PEs, and the integumentary system (including skin) was documented in two-thirds of PEs, vital signs and anthropometric measurements were explicitly documented as part of the PE in only about a quarter of all examinations. This discrepancy between clinical practice recommendations and trial protocols raises questions about whether important assessments might be overlooked or inconsistently performed across trial sites.

The authors note that current guideline documents for clinical trials, including ICH GCP, do not explicitly state that a PE must be included or define what a PE should entail. This regulatory gap may contribute to the inconsistency observed in trial protocols. The researchers suggest that this inconsistency could be addressed through the development of standard operating procedures (SOPs) for PE in clinical trials, which would promote standardization and improve data quality. They also emphasize the importance of balancing the need for comprehensive assessment with the principles of data minimization required by regulations such as GDPR.

Could Standardization Enhance Participant Safety and Efficiency?

For the clinical research community, these findings suggest an opportunity to reconsider the role of physical examinations in late-phase trials. The authors recommend being explicit about the purpose of PE in clinical trial protocols and consciously determining the appropriate scope and extent based on that purpose. This approach would not only enhance standardization but could also reduce unnecessary burden on participants and streamline trial operations. As decentralized clinical trials become more common, understanding which aspects of PE are truly essential will be crucial for determining which activities can be conducted remotely or modified to accommodate innovative trial designs.

Could the development of standardized, purpose-driven physical examination protocols improve the efficiency and quality of clinical trials while reducing participant burden? What alternative approaches might provide the same safety and data quality benefits as traditional physical examinations in the context of late-phase diabetes trials? These questions warrant further exploration as the field continues to evolve toward more patient-centered and efficient research methodologies.

Summary

A systematic review of 211 phase 3 and 4 type 2 diabetes mellitus clinical trials reveals that while 90% include physical examinations, documentation of these procedures is inconsistent and often incomplete. The study, conducted by the Trials@Home consortium, found that only 67% of protocols explicitly stated the purpose of physical examinations, 60% described which body systems should be examined, and merely 8% provided details on how examinations should be conducted. Despite widespread inclusion, the cardiovascular system was most frequently documented (95%), followed by respiratory (90%) and digestive systems (74%). The research highlights critical gaps in standardization across multi-site international trials, raising concerns about data quality and inter-observer variation. The findings suggest that physical examinations may be included more from convention than necessity, particularly relevant as the field moves toward decentralized trial approaches. The authors recommend explicit documentation of examination purposes, determination of appropriate scope based on those purposes, and exploration of alternative approaches such as telemedicine solutions. The study emphasizes the need for balance between comprehensive safety assessment and reducing participant burden, while questioning whether current regulatory guidelines adequately address physical examination requirements in clinical trials. These findings have significant implications for trial design, data quality, and the evolution toward more patient-centric research methodologies in diabetes clinical research.